Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 23Terminated 9Recruiting 6Unknown 5Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 137Breast 70Head & Neck 15Other solid neoplasm 9Tumor-Agnostic 6CNS 6NET 3Gynecologic 3Endocrine 3Thoracic 2Genitourinary 2Other neoplasm 1Dermatologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Adenocarcinoma 2

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Capecitabine × Tumor-Agnostic × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

National Cancer Institute, Naples

Phase 2 Recruiting
240 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04333706 2026-03-10

EMPOWER

University of Southern California

Phase 1/2 Recruiting
65 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡